ivWatch just announced winning the European CE Mark for its ivWatch Model 400 device, the only continuous monitor for timely detection of intravenous (IV) infiltrations and extravasations. IV delivered medication and fluids can accidentally leak outside of the vein into surrounding tissue, creating serious complications for patients.
The device works by shining visible and near-infrared light to monitor the subcutaneous tissue and measure changes in the optical properties of the tissue. When the device detects sufficient change in the optical properties of the tissue, it sounds an alarm. The company reports that its technology is very good at keeping low the number of false positives.
We recently interviewed Gary Warren, the President and CEO of ivWatch, who gave us an in-depth perspective on the company’s technology and its applications. In the latest announcement, Gary said, “Peripheral IV therapy is among the most common invasive hospital procedures performed worldwide. Having the ability to extend the only surveillance monitoring technology for early detection of these common IV complications to new markets will help improve patient safety and effectiveness of IV therapy on a much larger scale. Navigating the comprehensive process to secure these regulatory milestones not only makes ivWatch positioned for growth but gives us the ability to respond quickly to new opportunities.”
The device already has FDA clearance and is available for direct purchase from the company by hospitals and clinics.
Flashbacks: ivWatch Detects IV Infiltrations and Extravasations: Interview with Gary Warren, President and CEO…; ivWatch Monitors IV Placement Sites for Leakage Outside Veins…; Health Canada Issues Medical Device License to ivWatch…
Product page: ivWatch Model 400…